Epigenetics
Q&A
By Eva Kiesler, PhD, Science Writer/Editor  |  Friday, January 30, 2015

An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study.

In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, January 28, 2015

An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.

Pictured: José Baselga
Video
By Memorial Sloan Kettering  |  Thursday, January 15, 2015

MSK Physician-in-Chief José Baselga discusses the amazing progress that has been made in fighting cancer.

(From left) MSK investigators Michael Berger, José Baselga, and Maurizio Scaltriti, and graduate student Pau Castel.
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 17, 2014

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

Gregory Riely
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, November 12, 2014

MSK lung cancer patients benefit from a powerful genomic test that looks for mutations in 341 genes to help determine the best treatment.

DNA wrapped around histones
Decoder
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, October 14, 2014

Physician-scientist Omar Abdel-Wahab explains epigenetics, a growing field based on the study of genetic changes that are not part of the DNA code, and how it relates to cancer.

Pictured: Ping Chi
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, October 9, 2014

Genetic analysis reveals biomarkers and possible drug targets for malignant peripheral nerve sheath tumors.

Pictured: Gabriela Chiosis
Finding
By Celia Gittelson, BA  |  Thursday, July 17, 2014

A small molecule discovered at MSK called PU-H71 blocks the growth of cancer cells and enables doctors to image tumors.

Pictured: David Solit
Profile
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, May 27, 2014

David Solit, Director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, discusses how working with cancer patients drives him to develop more-effective, personalized cancer treatments.

Pictured: Mark Kris
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, May 21, 2014

A new study has found that driver mutations can be found in about two-thirds of lung adenocarcinomas, suggesting options for treatment with targeted therapies.

Pictured: José Baselga, Agnès Viale,  Michael Berger & David Solit
Announcement
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, May 20, 2014

With the creation of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering sets out to deliver on the promise of personalized medicine by creating better treatment options for all people with cancer.

pictured: Martin S. Tallman
Profile
By Maureen Salamon, BA, Freelance Writer  |  Monday, May 19, 2014

Leukemia Specialist Martin Tallman discusses how research has led to improvements in the treatment of leukemia and what challenges remain.

Pictured: William Tap
MSK at ASCO
By Media Staff  |  Thursday, May 15, 2014

New Memorial Sloan Kettering research demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of a rare and debilitating joint disease.

Pictured: Richard Steingart
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 19, 2014

Cancer treatments, both traditional treatments and newer targeted therapies, can lead to short-term and long-term heart problems.

Pictured: Diane Reidy
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, February 19, 2014

Cycle for Survival, Memorial Sloan Kettering’s nationwide indoor team cycling event, helps support research into rare cancers. Three researchers discuss how these funds benefit their research.

Center News

Stay Informed

Get the latest information about cancer care and research every month.